查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602803

抗癌藥物市場：按適應症、給藥途徑、藥物類別、分銷管道和最終用戶 - 2025-2030 年全球預測

Anti-Tumor Drugs Market by Indications (Breast Cancer, Leukemia, Lung Cancer), Route of Administration (Intra-muscular, Intraperitoneal, Intravenous), Drug Class, Distribution Channels, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗癌藥物市值為348.9億美元，預計2024年將達到391.4億美元，複合年成長率為12.24%，到2030年將達到783.5億美元。

抗癌藥物市場包括專門針對癌細胞配製的藥物的開發、生產和分銷。對這個市場的需求源於解決各種形式的癌症的迫切需要，這些癌症仍然是全世界發病和死亡的主要原因。治療應用包括許多癌症類型，包括乳癌、肺癌、大腸癌和攝護腺癌，最終用途主要是醫院、癌症治療中心和研究機構。關鍵的成長要素包括癌症發生率上升、給藥技術的進步、研發投資的增加以及更容易罹患癌症的老年人口的增加。此外，隨著政府和醫療機構大力投資癌症治療基礎設施並促進創新治療方法的快速核准，市場機會正在擴大。

主要市場統計
基準年[2023] 348.9億美元
預測年份 [2024] 391.4億美元
預測年份 [2030] 783.5億美元
複合年成長率（%） 12.24%

個人化醫療和免疫療法充滿機會。客製化治療和利用免疫系統對抗腫瘤的趨勢可能會帶來更有效、毒性更小的治療方法選擇。因此，基因組學和生物技術領域的夥伴關係和合作提供了良好的前景。然而，市場面臨著高昂的治療成本、嚴格的監管要求、某些藥物相關的副作用以及來自替代療法的競爭等挑戰，這些可能會限制成長。有效利用全球法律規範並專注於具有成本效益的解決方案有可能緩解這些挑戰。

創新應以提高藥物療效和減少副作用為目標，例如藥物傳輸中的奈米技術、基於 CRISPR 的基因研究以及人工智慧支援的藥物發現過程。聯合治療的研究也可能產生有希望的結果。這個市場的本質是動態的，受到不斷的技術進步和對更新、更有效的治療方案的持續需求的推動。因此，對於希望在競爭激烈的市場環境中發展的公司來說，掌握技術創新、監管變化和患者需求至關重要。透過實施穩健的市場分析來獲得策略優勢，以在不斷變化的治療範式中保持領先地位。

市場動態：揭示快速發展的抗癌藥物市場的關鍵市場洞察

供需的動態交互作用正在改變抗癌藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 老年人口迅速增加導致癌症發生率上升
    • 提高對癌症早期診斷和治療的認知
    • 政府增加醫療保健支出
  • 市場限制因素
    • 抗癌藥物高成本、存活率低
  • 市場機會
    • 管道藥物的可用性和腫瘤治療個人化藥物的需求不斷成長
    • 抗癌藥物治療的最新創新
  • 市場挑戰
    • 與抗癌藥物使用相關的不良後果

波特五力：駕馭抗癌藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解外部對抗癌藥物市場的影響

外部宏觀環境因素對抗癌藥物市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解抗癌藥物市場競爭狀況

透過對抗癌藥物市場的詳細市場佔有率分析，可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣抗癌藥物市場供應商績效評估

FPNV定位矩陣是評估抗癌藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議描繪抗癌藥物市場的成功之路

抗癌藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 老年人口迅速增加導致癌症發生率增加
      • 提高對癌症早期診斷和治療的認知
      • 政府增加醫療保健支出
    • 抑制因素
      • 抗癌藥物高成本、存活率低
    • 機會
      • 管道藥物的供應量和腫瘤治療個人化藥物的需求迅速增加
      • 抗癌治療的最新創新
    • 任務
      • 與使用抗癌藥物相關的不利後果
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

抗癌藥物適應症市場

  • 乳癌
  • 白血病
  • 肺癌
  • 惡性黑色素瘤
  • 攝護腺癌

抗癌藥物市場：依給藥途徑

  • 肌肉注射
  • 腹膜內
  • 靜脈
  • 腦室內或脊椎內
  • 囊泡內
  • 口服
  • 皮下的
  • 話題

抗癌藥物市場

  • 細胞毒性物質
  • 荷爾蒙療法
  • 標靶治療
    • 單株抗體
    • 小分子抑制劑

第9章按通路分類的抗癌藥物市場

  • 醫院藥房
  • 零售藥房

第10章抗癌藥物市場：依最終用戶分類

  • 診所
  • 醫院
  • 專業中心

第11章 美洲抗癌藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太抗癌藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲抗癌藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Amgen inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cybrexa Therapeutics
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Getwell Oncology
  • GLS Pharma Pvt. Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer Inc.
  • PharmaMar
  • Sanofi SA
  • Taiho Oncology, Inc
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-710B1F0AC60D

The Anti-Tumor Drugs Market was valued at USD 34.89 billion in 2023, expected to reach USD 39.14 billion in 2024, and is projected to grow at a CAGR of 12.24%, to USD 78.35 billion by 2030.

The anti-tumor drugs market involves the development, production, and distribution of pharmaceutical agents specifically formulated to combat tumor cells. This market's necessity stems from the urgent need to address various forms of cancer, which continue to be a leading cause of morbidity and mortality globally. Application spans numerous cancer types, including breast, lung, colorectal, prostate, and others, with end-use primarily among hospitals, cancer treatment centers, and research institutions. Key growth factors include rising cancer prevalence, advancements in drug delivery technologies, increasing investment in R&D, and a growing elderly population more susceptible to cancer. Furthermore, governments and healthcare organizations are investing heavily in cancer treatment infrastructure, promoting the expedited approval of innovative treatments, thus expanding market opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 34.89 billion
Estimated Year [2024] USD 39.14 billion
Forecast Year [2030] USD 78.35 billion
CAGR (%) 12.24%

Opportunities abound in personalized medicine and immunotherapy; the trend towards tailored treatments and leveraging the immune system to fight tumors could lead to more effective and less toxic therapy options. As such, partnerships and collaborations in genomics and biotechnology present lucrative prospects. However, the market faces challenges such as high treatment costs, stringent regulatory requirements, side effects associated with certain drugs, and competition from alternative treatments, which may limit growth. Effective navigation through global regulatory frameworks and focusing on cost-effective solutions could mitigate some of these challenges.

Innovation should target improving drug efficacy and reducing side effects, with specific focus areas including nanotechnology in drug delivery, CRISPR-based genetic research, and AI-driven drug discovery processes. Research into combination therapies could also yield promising results. The nature of this market is dynamic, driven by continuous technological advancements and a consistent demand for newer, more effective treatment options. Therefore, staying abreast of technological innovations, regulatory changes, and patient needs is critical for businesses aspiring to achieve growth in the competitive anti-tumor drugs market landscape. Implementing robust market analytics to preemptively identify shifts in treatment paradigms can offer a strategic advantage.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Tumor Drugs Market

The Anti-Tumor Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in incidence of cancer with the surge in the geriatric population
    • Growing awareness regarding early diagnosis and treatment for the cancer
    • Increase in expenditures on healthcare by government
  • Market Restraints
    • High cost of anticancer drugs and low survival rate
  • Market Opportunities
    • Availability of pipelined drugs and upsurge in demand for personalized medicines for the tumor treatment
    • Recent innovations in anticancer therapies
  • Market Challenges
    • Unfavorable outcomes associated with the use of cancer drugs

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Tumor Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Tumor Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Tumor Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Tumor Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Tumor Drugs Market

A detailed market share analysis in the Anti-Tumor Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Tumor Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Tumor Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Tumor Drugs Market

A strategic analysis of the Anti-Tumor Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Tumor Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Cybrexa Therapeutics, Dr. Reddy's Laboratories Ltd., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Getwell Oncology, GLS Pharma Pvt. Ltd., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., PharmaMar, Sanofi SA, Taiho Oncology, Inc, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Anti-Tumor Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indications, market is studied across Breast Cancer, Leukemia, Lung Cancer, Melanoma, and Prostate Cancer.
  • Based on Route of Administration, market is studied across Intra-muscular, Intraperitoneal, Intravenous, Intraventricular or Intrathecal, Intravesicular, Oral, Subcutaneous, and Topical.
  • Based on Drug Class, market is studied across Cytotoxics, Hormonal Therapy, and Targeted Therapy. The Targeted Therapy is further studied across Monoclonal Antibodies and Small Molecule Inhibitors.
  • Based on Distribution Channels, market is studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on End User, market is studied across Clinics, Hospitals, and Specialty Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in incidence of cancer with the surge in the geriatric population
      • 5.1.1.2. Growing awareness regarding early diagnosis and treatment for the cancer
      • 5.1.1.3. Increase in expenditures on healthcare by government
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of anticancer drugs and low survival rate
    • 5.1.3. Opportunities
      • 5.1.3.1. Availability of pipelined drugs and upsurge in demand for personalized medicines for the tumor treatment
      • 5.1.3.2. Recent innovations in anticancer therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Unfavorable outcomes associated with the use of cancer drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Tumor Drugs Market, by Indications

  • 6.1. Introduction
  • 6.2. Breast Cancer
  • 6.3. Leukemia
  • 6.4. Lung Cancer
  • 6.5. Melanoma
  • 6.6. Prostate Cancer

7. Anti-Tumor Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intra-muscular
  • 7.3. Intraperitoneal
  • 7.4. Intravenous
  • 7.5. Intraventricular or Intrathecal
  • 7.6. Intravesicular
  • 7.7. Oral
  • 7.8. Subcutaneous
  • 7.9. Topical

8. Anti-Tumor Drugs Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Cytotoxics
  • 8.3. Hormonal Therapy
  • 8.4. Targeted Therapy
    • 8.4.1. Monoclonal Antibodies
    • 8.4.2. Small Molecule Inhibitors

9. Anti-Tumor Drugs Market, by Distribution Channels

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Retail Pharmacies

10. Anti-Tumor Drugs Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Hospitals
  • 10.4. Specialty Centers

11. Americas Anti-Tumor Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Anti-Tumor Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Anti-Tumor Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Biogen Inc.
  • 7. Bristol-Myers Squibb Company
  • 8. Celgene Corporation
  • 9. Cybrexa Therapeutics
  • 10. Dr. Reddy's Laboratories Ltd.
  • 11. Eisai Co., Ltd.
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann-La Roche Ltd
  • 14. Genentech, Inc.
  • 15. Getwell Oncology
  • 16. GLS Pharma Pvt. Ltd.
  • 17. Merck & Co., Inc.
  • 18. Novartis AG
  • 19. Otsuka Pharmaceutical Co., Ltd
  • 20. Pfizer Inc.
  • 21. PharmaMar
  • 22. Sanofi SA
  • 23. Taiho Oncology, Inc
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTI-TUMOR DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-TUMOR DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANTI-TUMOR DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANTI-TUMOR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-TUMOR DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-TUMOR DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRA-MUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENTRICULAR OR INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVESICULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CYTOTOXICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 140. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 146. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 152. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 165. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 171. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 177. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 183. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 189. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 195. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 201. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 213. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 219. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 225. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 231. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 237. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 255. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 261. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 273. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. ANTI-TUMOR DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 287. ANTI-TUMOR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023